Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?

Key Takeaways NVO is pursuing approval for Wegovy 7.2 mg to counter slowing sales amid rising GLP-1 competition.STEP UP showed Wegovy 7.2 mg delivered 20.7% average weight loss vs 17.5% with the 2.4 mg dose.NVO has filed for the approval of Wegovy 7.2 mg in the U.S. and EU, with decisions expected in 2026.Novo Nordisk (NVO) is a leading player in the obesity market, driven by its blockbuster GLP-1 therapy Wegovy (semaglutide). However, despite being a core growth driver, Wegovy’s sales momentum has slowed i ...